News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in MedicineShorts
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Emerging Pharma Leaders Awards|
Latest Executive Roundtables|
Asembia 2025 |
Sales Effectiveness
Advertisement

Michael Murphy, MD, PhD

Advertisement

Chief Medical and Scientific Officer, Worldwide Clinical Trials

Articles by Michael Murphy, MD, PhD

Your Phase III Clinical Protocol Is Your Initial Product Launch

ByHarris Kaplan,Michael Murphy, MD, PhD
January 30th 2026

How demand-driven development will help new products be more successful.

Advertisement

Latest Updated Articles

  • Your Phase III Clinical Protocol Is Your Initial Product Launch
    Your Phase III Clinical Protocol Is Your Initial Product Launch

    January 30th 2026



Advertisement
Advertisement

Trending on PharmExec

1

Roche and C4 Therapeutics Expands Partnership with $1 Billion Collaboration Agreement

2

Shionogi Inc. Awarded $482 Million Contract with U.S. Government to Enhance National Preparedness for Drug-Resistant Bacterial Threats

3

Lipid Lowering with PCSK9 Inhibition: Long-Term Efficacy, Long-Standing Barriers

4

Pharmaceutical Executive Daily: Shah Capital's Plan to Vote Against Novavax Board Nominees

5

Aradhana Sarin: The CFO as a Catalyst

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us